Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;40(11):5090-5101.
doi: 10.1007/s12325-023-02669-w. Epub 2023 Sep 22.

The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases

Darmendra Ramcharran  1   2 , Bruce Strober  3   4 , Kenneth Gordon  5 , Cynthia DeKlotz  6 , Steven Fakharzadeh  7 , Ya-Wen Yang  7 , Joel Swerdel  8 , Jill Hardin  8 , Sridhar Dronavalli  9 , Amy S Paller  10
Affiliations

The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases

Darmendra Ramcharran et al. Adv Ther. 2023 Nov.

Abstract

Background: Palmoplantar pustulosis (PPP) is a chronic inflammatory condition characterized by sterile pustules on the palms and soles. This study evaluated the epidemiology of PPP using claims and electronic health record (EHR) databases.

Methods: Patients coded for PPP in the United States (US) and Japan from 2016 to 2020 were identified. Several PPP definitions were evaluated; the specific definition (≥ 2 visits coded for PPP, the second 31-730 days after diagnosis) was chosen for characterizing PPP epidemiology. Baseline characteristics and pre- and post-diagnosis treatments were summarized. Prevalence and incidence rates were analyzed by calendar year, sex, age, and database.

Results: Prevalence and incidence of PPP were higher in Japan than the US. PPP prevalence increased over time. PPP occurred predominantly in adulthood and was more common among women. Features of metabolic syndromes, anxiety, and depression were more common among US PPP patients. Consistently high baseline use of anti-bacterial, anti-inflammatory/anti-rheumatic, and obstructive airway disease treatments was observed among PPP patients. Potential miscoding or misclassification of PPP limited this analysis. Prevalence estimates from databases may differ from field- and population-based approaches.

Conclusions: The burden of PPP was greater in Japan than in the US. Additional studies are needed to further elucidate PPP epidemiology worldwide.

Keywords: Epidemiology; Incidence; Japan; Palmoplantar pustulosis; Prevalence; United States.

PubMed Disclaimer

Conflict of interest statement

At the time the research was conducted, Darmendra Ramcharran was an employee of Janssen Research & Development; he is currently an employee of GSK. Bruce Strober served as a consultant (honoraria) and/or speaker and/or investigator for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Connect Biopharma, CorEvitas Psoriasis Registry, Dermavant, Dermira, Eli Lilly, EPI Health, Evelo Biosciences, Immunic Therapeutics, Incyte, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ono, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, UCB Pharma, Union Therapeutics, Ventyxbio, and vTvt Therapeutics; served as co-Scientific Director (consulting fee) of CorEvitas (formerly Corrona) Psoriasis Registry and Editor-in-Chief (honorarium) of Journal of Psoriasis and Psoriatic Arthritis. Kenneth Gordon received research/grant support from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma, and honoraria for consultation from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, Novartis, and UCB Pharma. Amy Paller has been an investigator for AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, and UCB; a consultant with honorarium for Aegerion Pharma, Azitra, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek, Eli Lilly, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy, TWI Biotechnology, and UCB; and is on data safety monitoring boards for AbbVie, Abeona, Catawba, Galderma, and InMed. Cynthia DeKlotz, Joel Swerdel, and Jill Hardin are employees of Janssen Research & Development and Steven Fakharzadeh and Ya-Wen Yang are employees of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson; employees may own stock in Johnson & Johnson, of which Janssen is a subsidiary. Sridhar Dronavalli has no conflicts to disclose.

Figures

Fig. 1
Fig. 1
Prevalence using the specific PPP definition by database, aage, and sex. aOnly US databases are shown; see Fig. 2 for prevalence based on the specific PPP definition in JMDC. MDCR includes only adults ≥ 65 years of age; thus, data from MDCR were excluded from the figure to facilitate interpretability of the graphs. PPP palmoplantar pustulosis, EHR Optum® de-identified Electronic Health Record Database, SES Optum’s Clinformatics® de-identified Data Mart Database, CCAE IBM® MarketScan® Commercial Database, MDCD IBM® MarketScan® Multi-State Medicaid Database, MDCR IBM® MarketScan® Medicare Supplemental Database, US United States
Fig. 2
Fig. 2
Incidence rates using the specific PPP definition by database, age, and sex. PPP palmoplantar pustulosis, JMDC Japan Medical Data Center, EHR Optum® de-identified Electronic Health Record Database, SES Optum’s Clinformatics® de-identified Data Mart Database, CCAE IBM® MarketScan® Commercial Database, MDCD IBM® MarketScan® Multi-State Medicaid Database, MDCR IBM® MarketScan® Medicare Supplemental Database, US United States
See this image and copyright information in PMC

References

    1. Yamamoto T. Clinical characteristics of Japanese patients with palmoplantar pustulosis. Clin Drug Investig. 2019;39(3):241–252. doi: 10.1007/s40261-018-00745-6. - DOI - PubMed
    1. Misiak-Galazka M, Wolska H, Rudnicka L. What do we know about palmoplantar pustulosis? J Eur Acad Dermatol Venereol. 2017;31(1):38–44. doi: 10.1111/jdv.13846. - DOI - PubMed
    1. Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020;98(1):13–19. doi: 10.1016/j.jdermsci.2020.03.003. - DOI - PubMed
    1. Benzaquen M, Flachaire B, Rouby F, Berbis P, Guis S. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int. 2018;38(7):1297–1299. doi: 10.1007/s00296-018-4034-0. - DOI - PubMed
    1. Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355–370. doi: 10.1007/s40257-020-00503-5. - DOI - PMC - PubMed

Publication types